日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.

利用他汀类药物和吩噻嗪类药物治疗化疗耐药性神经母细胞瘤。

Radke Katarzyna, Aaltonen Kristina, Muciño-Olmos Erick A, Esfandyari Javanshir, Adamska Aleksandra, Siaw Joachim T, Adamic Dora, Lago Chiara, Mañas Adriana, Seger Alexandra, Hansson Karin, Rogova Oksana, Lehn Sophie, Mason Daniel J, O'Donovan Daniel J, Roberts Ian, Lock Antonia, Brennan Jane, Pietras Kristian, Davies Emma J, Spégel Peter, Bedoya-Reina Oscar C, Brown David, Thompson Neil T, Spadoni Cesare, Bexell Daniel

A novel combination treatment for fragile X syndrome predicted using computational methods

利用计算方法预测脆性X综合征的新型联合治疗方案

Chadwick, Wayne; Angulo-Herrera, Ivan; Cogram, Patricia; Deacon, Robert J M; Mason, Daniel J; Brown, David; Roberts, Ian; O'Donovan, Daniel J; Tranfaglia, Michael R; Guilliams, Tim; Thompson, Neil T

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

在非小细胞肺癌中,酪氨酸激酶抑制剂耐药性的出现可通过一线联合使用 HSP90 抑制剂奥纳莱斯皮来延缓。

Courtin, Aurelie; Smyth, Tomoko; Hearn, Keisha; Saini, Harpreet K; Thompson, Neil T; Lyons, John F; Wallis, Nicola G

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models

HSP90抑制剂AT13387对伊马替尼敏感和耐药的胃肠道间质瘤模型均有效。

Smyth, Tomoko; Van Looy, Thomas; Curry, Jayne E; Rodriguez-Lopez, Ana M; Wozniak, Agnieszka; Zhu, Meijun; Donsky, Rachel; Morgan, Jennifer G; Mayeda, Mark; Fletcher, Jonathan A; Schöffski, Patrick; Lyons, John; Thompson, Neil T; Wallis, Nicola G

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.

热休克蛋白 90 抑制剂 AT13387 在体外和体内对非小细胞肺癌均表现出较长的作用时间

Graham Brent, Curry Jayne, Smyth Tomoko, Fazal Lynsey, Feltell Ruth, Harada Isobel, Coyle Joe, Williams Brian, Reule Matthias, Angove Hayley, Cross David M, Lyons John, Wallis Nicola G, Thompson Neil T

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

新型强效 AKT 抑制剂 CCT128930 的临床前药理学、抗肿瘤活性及药效学标志物的开发

Yap, Timothy A; Walton, Mike I; Hunter, Lisa-Jane K; Valenti, Melanie; de Haven Brandon, Alexis; Eve, Paul D; Ruddle, Ruth; Heaton, Simon P; Henley, Alan; Pickard, Lisa; Vijayaraghavan, Gowri; Caldwell, John J; Thompson, Neil T; Aherne, Wynne; Raynaud, Florence I; Eccles, Suzanne A; Workman, Paul; Collins, Ian; Garrett, Michelle D